ABBOTT LABORATORIES (ABT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$112.65

From 52W high−11.99%

Volume4.77M

Market cap$198.87B

P/E (TTM)42.6x

P/S (TTM)4.1x

Div yield2.19%

Key dataNov 4, 2026

Open

$112.65

From 52W high

−11.99%

Volume

4.77M

Market cap

$198.87B

ValuationView details →

P/E (Fwd)

19.7x

EV/EBITDA

—

P/E (TTM)

42.6x

RSI (14)

72.6

MomentumView details →

1D Return

+5.05%

YTD Return

−8.49%

SummaryUpdated Sep 1, 2026

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company founded in 1888 and headquartered in North Chicago, Illinois. Originally established as a pharmaceutical company by Dr. Wallace Calvin Abbott, the company has evolved over more than 135 years into one of the world's largest healthcare corporations. Abbott operates across four major business segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products, serving patients and healthcare providers in over 160 countries worldwide.

Ask drillr about ABBOTT LABORATORIES →

ValuationView details →

P/E (Fwd)

19.7x

P/E (TTM)

42.6x

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

4.1x

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

57.12%

Net Margin

9.75%

EBITDA Margin

20.13%

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

+10.00%

EPS YoY

−66.45%

FCF YoY

+6.91%

Revenue CAGR 3Y

+0.51%

EPS CAGR 3Y

−1.72%

EBITDA YoY

−17.69%

MomentumView details →

1D Return

+5.05%

YTD Return

−8.49%

1Y Return

−7.94%

RSI (14)

72.6

vs 50D SMA

+10.20%

vs 200D SMA

+12.92%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

2.19%

Div Rate

$2.52

Div Growth 1Y

+6.78%

EarningsView details →

EPS (Actual)

$1.42

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

$1.64

Avg Surprise (4Q)

0.74%

Rev Surprise

0.45%

Financials snapshotView financials →

Revenue (TTM)

48.23B

Net Income (TTM)

4.70B

Op. CF (TTM)

—

Next earningsJan 28, 2027 →

Latest newsMore news →

ABBOTT LABORATORIES Medical Japan launched a catheter-based treatment device for atrial fibrillation that enables procedures without general anesthesia.10h ago

BridgeBio announced that two moderated posters and three posters on acoramidis and ATTR-CM, plus a BridgeBio-supported poster led by ABBOTT LABORATORIES, are scheduled for presentation at the American Heart Association, Inc. Scientific Sessions 2026.1d ago

Similar companies

T&L Co., Ltd.340570.KQ Sky Labs Inc.386380.KQ Value Added Technology Co., Ltd.043150.KQ Vieworks Co., Ltd.100120.KQ Medtronic plcMDT Shinhung Co., Ltd004080.KS Find similar companies →

Latest newsMore news →

ABBOTT LABORATORIES Medical Japan launched a catheter-based treatment device for atrial fibrillation that enables procedures without general anesthesia.10h ago BridgeBio announced that two moderated posters and three posters on acoramidis and ATTR-CM, plus a BridgeBio-supported poster led by ABBOTT LABORATORIES, are scheduled for presentation at the American Heart Association, Inc. Scientific Sessions 2026.1d ago